WILMINGTON, DE — Delaware-based biopharmaceutical company, Prelude Therapeutics Incorporated, is set to present preclinical data on three of its innovative cancer drug candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024. The presentations will focus on Prelude’s oral SMARCA2 degrader, its CDK9 inhibitor and its next-generation CDK4/6 inhibitor.
The company’s Chief Scientific Officer, Peggy Scherle, Ph.D., expressed anticipation about sharing their findings. “We look forward to sharing data on the preclinical characterization of our lead oral SMARCA2 degrader, PRT7732, which is on track to advance into Phase 1 clinical development in the second half of this year,” said Scherle. She also highlighted the potential therapeutic value of the company’s CDK9 inhibitor, PRT2527, and its next-generation CDK4/6 inhibitor, PRT3645, in treating various types of cancer.
The first presentation will cover the preclinical characterization of PRT7732, a targeted protein degrader of SMARCA2. SMARCA2 is a gene that codes for a protein involved in chromatin remodeling, a process crucial for DNA repair, replication, and transcription. The disruption of this process has been implicated in several types of cancer.
The second presentation will detail the antitumor activity of PRT2527, a highly selective Cyclin-Dependent Kinase 9 (CDK9) inhibitor. CDK9 is a protein kinase that plays a vital role in promoting cellular growth and proliferation, making it a promising target for cancer therapy.
The final presentation will showcase the effectiveness of the brain penetrant CDK4/6 inhibitor, PRT3645, in combination with other targeted therapies in preclinical models of breast cancer, colorectal cancer (CRC), and non-small cell lung cancer (NSCLC). CDK4/6 inhibitors are a class of drugs that block the activity of proteins known as cyclin-dependent kinases, which are involved in cell division and growth.
In addition to these presentations, Prelude will host a live webcast “Let’s Talk SMARCA” Teach-In on April 5, focusing on the basic science behind the role of SMARCA in chromatin remodeling and its potential clinical relevance in multiple cancers.
The AACR Annual Meeting 2024, taking place from April 5 to 10, is one of the most prominent events in the field of cancer research, drawing researchers, clinicians, and industry representatives from around the world. The inclusion of Prelude’s research in this event underscores the company’s ongoing efforts to develop novel therapeutic strategies for cancer treatment.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.